J Allergy Clin Immunol

AAAAI Conference: neffy effective for treating anaphylactic symptoms in children after oral food challenge

March 5, 2024

In this phase 3 study, the efficacy and safety of a single dose of neffy, an epinephrine nasal spray, was assessed in pediatric patients with allergy symptoms induced by an oral food challenge. Researchers found that the single dose proved to be an effective, needle-free option for the treatment of anaphylactic symptoms. These findings were presented in February at the 2024 American Academy of Allergy, Asthma, & Immunology Annual Meeting (AAAAI) in Washington, D.C.

• The study included 15 patients (n=6 for 1 mg and n=9 for 2 mg) aged 6 to 17 years of age who were dosed with neffy when exhibiting respiratory, gastrointestinal, or circulatory symptoms that were grade 2 or higher, according to the Severity Classification of Organ Symptoms by the Japanese Society of Allergology Anaphylaxis Guidelines 2022.
• No patients needed a second dose of epinephrine within 15 minutes post-dose.
• The median time to symptom resolution was 16 min (range, 1 - 90 min).
• One patient had a biphasic reaction 2h and 45 min after initial neffy dosing and required additional epinephrine treatment.
• Seven patients exhibited adverse events, all of which were mild or moderate and mostly resolved quickly.

Source:

Ebisawa, M et al. (2024, February). J Allergy Clin Immunol. neffy, epinephrine nasal spray, demonstrates a positive efficacy and safety profile for the treatment of allergic reactions in pediatric patients at-risk of anaphylaxis: phase 3 study results. https://www.jacionline.org/article/S0091-6749(23)02379-5/fulltext